1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Increased	_	_	VBN	_	_	_	_	_
2	selectivity	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	efficacy	_	_	NN	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	achieved	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	linking	_	_	VBG	_	_	_	_	_
10	cytotoxic	_	_	JJ	_	_	_	_	_
11	anticancer	_	_	NN	_	_	_	_	_
12	drugs	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	specific	_	_	JJ	_	_	_	_	_
15	target/carrier	_	_	NN	_	_	_	_	_
16	molecules	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Successful	_	_	JJ	_	_	_	_	_
2	examples	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	treatment	_	_	NN	_	_	_	_	_
6	strategy	_	_	NN	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	antibody-drug	_	_	JJ	_	_	_	_	_
9	conjugates	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	target	_	_	VBP	_	_	_	_	_
13	cancer	_	_	NN	_	_	_	_	_
14	cells	_	_	NNS	_	_	_	_	_
15	due	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	increased	_	_	VBN	_	_	_	_	_
18	expression	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	specific	_	_	JJ	_	_	_	_	_
21	proteins	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	folate	_	_	NN	_	_	_	_	_
25	conjugates	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	which	_	_	WDT	_	_	_	_	_
28	utilize	_	_	VBP	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	commonly	_	_	RB	_	_	_	_	_
31	high	_	_	JJ	_	_	_	_	_
32	expression	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	folate	_	_	NN	_	_	_	_	_
36	receptor	_	_	NN	_	_	_	_	_
37	(	_	_	-LRB-	_	_	_	_	_
38	FR	_	_	NN	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	on	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	surface	_	_	NN	_	_	_	_	_
43	of	_	_	IN	_	_	_	_	_
44	different	_	_	JJ	_	_	_	_	_
45	human	_	_	JJ	_	_	_	_	_
46	cancer	_	_	NN	_	_	_	_	_
47	cells	_	_	NNS	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_


1	Warburg	_	_	NNP	_	_	_	_	_
2	effect	_	_	NN	_	_	_	_	_
3	targeting	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	another	_	_	DT	_	_	_	_	_
6	promising	_	_	JJ	_	_	_	_	_
7	strategy	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	design	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	synthesis	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	new	_	_	JJ	_	_	_	_	_
15	cytotoxic	_	_	JJ	_	_	_	_	_
16	anticancer	_	_	NN	_	_	_	_	_
17	drugs	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	conjugation	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	sugar	_	_	NN	_	_	_	_	_
7	residues	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	cytotoxic	_	_	JJ	_	_	_	_	_
10	drugs	_	_	NNS	_	_	_	_	_
11	shall	_	_	MD	_	_	_	_	_
12	increase	_	_	VB	_	_	_	_	_
13	selectivity	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	cancerous	_	_	JJ	_	_	_	_	_
16	tissues	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	reduce	_	_	VB	_	_	_	_	_
19	side	_	_	NN	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	due	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	higher	_	_	JJR	_	_	_	_	_
27	sugar	_	_	NN	_	_	_	_	_
28	uptake	_	_	NN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	cancer	_	_	NN	_	_	_	_	_
32	cells	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	date	_	_	VB	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	sugar-conjugated	_	_	JJ	_	_	_	_	_
5	molecule	_	_	NN	_	_	_	_	_
6	glufosfamide	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	clinical	_	_	JJ	_	_	_	_	_
10	development	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	treatment	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	lung	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	ovary	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	pancreatic	_	_	JJ	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	brain	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	CNS	_	_	NN	_	_	_	_	_
24	cancer	_	_	NN	_	_	_	_	_
25	as	_	_	RB	_	_	_	_	_
26	well	_	_	RB	_	_	_	_	_
27	as	_	_	IN	_	_	_	_	_
28	soft	_	_	JJ	_	_	_	_	_
29	tissue	_	_	NN	_	_	_	_	_
30	sarcoma	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	different	_	_	JJ	_	_	_	_	_
5	sugar-conjugated	_	_	JJ	_	_	_	_	_
6	molecules	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	currently	_	_	RB	_	_	_	_	_
9	evaluated	_	_	VBN	_	_	_	_	_
10	preclinically	_	_	RB	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	prostate	_	_	NN	_	_	_	_	_
3	cancer	_	_	NN	_	_	_	_	_
4	Warburg	_	_	NNP	_	_	_	_	_
5	effect	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	observed	_	_	VBN	_	_	_	_	_
8	specifically	_	_	RB	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	metastatic	_	_	JJ	_	_	_	_	_
11	tumors	_	_	NNS	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	makes	_	_	VBZ	_	_	_	_	_
14	glucose-derived	_	_	JJ	_	_	_	_	_
15	chemotherapeutics	_	_	NNS	_	_	_	_	_
16	promising	_	_	JJ	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	metastatic	_	_	JJ	_	_	_	_	_
22	CRPC	_	_	NNP	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	research	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	found	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	derivatives	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	natural	_	_	JJ	_	_	_	_	_
11	1,4-naphtoquinone	_	_	NN	_	_	_	_	_
12	compounds	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	active	_	_	JJ	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	drug-resistant	_	_	JJ	_	_	_	_	_
18	prostate	_	_	NN	_	_	_	_	_
19	cancer	_	_	NN	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Preliminary	_	_	JJ	_	_	_	_	_
2	data	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	however	_	_	RB	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	shown	_	_	VBN	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	these	_	_	DT	_	_	_	_	_
10	substances	_	_	NNS	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	also	_	_	RB	_	_	_	_	_
13	rather	_	_	RB	_	_	_	_	_
14	cytotoxic	_	_	JJ	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	non-cancerous	_	_	JJ	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	suggesting	_	_	VBG	_	_	_	_	_
20	undesired	_	_	JJ	_	_	_	_	_
21	side	_	_	NN	_	_	_	_	_
22	effects	_	_	NNS	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	vivo	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	utilized	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	Warburg	_	_	NNP	_	_	_	_	_
7	effect	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	order	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	increase	_	_	VB	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	selectivity	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	compounds	_	_	NNS	_	_	_	_	_
17	towards	_	_	IN	_	_	_	_	_
18	tumor	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	synthesized	_	_	VBD	_	_	_	_	_
3	hybrid	_	_	JJ	_	_	_	_	_
4	molecules	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	which	_	_	WDT	_	_	_	_	_
7	contain	_	_	VBP	_	_	_	_	_
8	selected	_	_	VBN	_	_	_	_	_
9	natural	_	_	JJ	_	_	_	_	_
10	1,4-naphtoquinone	_	_	NN	_	_	_	_	_
11	moieties	_	_	NNS	_	_	_	_	_
12	conjugated	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	glucose	_	_	NN	_	_	_	_	_
15	residues	_	_	NNS	_	_	_	_	_
16	via	_	_	IN	_	_	_	_	_
17	non-glycoside	_	_	JJ	_	_	_	_	_
18	bond	_	_	NN	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	C6	_	_	NNP	_	_	_	_	_
21	position	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	non-glycoside	_	_	JJ	_	_	_	_	_
3	nature	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	conjugates	_	_	NNS	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	chosen	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	order	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	provide	_	_	VB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	highest	_	_	JJS	_	_	_	_	_
15	affinity	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	glucose	_	_	NN	_	_	_	_	_
18	transporters	_	_	NNS	_	_	_	_	_
19	located	_	_	VBN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	cellular	_	_	JJ	_	_	_	_	_
23	membrane	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	known	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	presence	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	free	_	_	JJ	_	_	_	_	_
9	unsubstituted	_	_	JJ	_	_	_	_	_
10	glycoside	_	_	NN	_	_	_	_	_
11	hydroxyl	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	at	_	_	IN	_	_	_	_	_
14	C1	_	_	NN	_	_	_	_	_
15	position	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	important	_	_	JJ	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	stabilization	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	hydrogen	_	_	NN	_	_	_	_	_
24	bonding	_	_	NN	_	_	_	_	_
25	interactions	_	_	NNS	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	GLUT-1	_	_	NNP	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	therefore	_	_	RB	_	_	_	_	_
30	is	_	_	VBZ	_	_	_	_	_
31	required	_	_	VBN	_	_	_	_	_
32	for	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	successful	_	_	JJ	_	_	_	_	_
35	cellular	_	_	JJ	_	_	_	_	_
36	uptake	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	sugar-conjugated	_	_	JJ	_	_	_	_	_
40	molecules	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	hydroxyl	_	_	NN	_	_	_	_	_
6	at	_	_	IN	_	_	_	_	_
7	C6	_	_	NN	_	_	_	_	_
8	position	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	glucose	_	_	NN	_	_	_	_	_
11	molecule	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	not	_	_	RB	_	_	_	_	_
14	relevant	_	_	JJ	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	hydrogen	_	_	NN	_	_	_	_	_
18	bond	_	_	NN	_	_	_	_	_
19	interactions	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	therefore	_	_	RB	_	_	_	_	_
22	it	_	_	PRP	_	_	_	_	_
23	â€™s	_	_	VBZ	_	_	_	_	_
24	substitution	_	_	NN	_	_	_	_	_
25	may	_	_	MD	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	more	_	_	RBR	_	_	_	_	_
28	tolerable	_	_	JJ	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	affinity	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	glucose	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	substituted	_	_	VBN	_	_	_	_	_
10	C6-OH	_	_	NNP	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	GLUT-1	_	_	NNP	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	reported	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	almost	_	_	RB	_	_	_	_	_
18	equal	_	_	JJ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	its	_	_	PRP$	_	_	_	_	_
21	unsubstituted	_	_	JJ	_	_	_	_	_
22	analogues	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	instead	_	_	RB	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	conventional	_	_	JJ	_	_	_	_	_
7	glycosylation	_	_	NN	_	_	_	_	_
8	reaction	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	results	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	C1-substituted	_	_	JJ	_	_	_	_	_
13	glucose	_	_	NN	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	we	_	_	PRP	_	_	_	_	_
16	applied	_	_	VBD	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	new	_	_	JJ	_	_	_	_	_
19	reaction	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	alkylation	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	2-hydroxy-1,4-naphthoquinones	_	_	NN	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	6-deoxy-6-iodo-1,2:3,5-di-O-	_	_	NN	_	_	_	_	_
26	isopropylidene-Î±-D-glucofuranose	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	results	_	_	NNS	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	C6-substituted	_	_	JJ	_	_	_	_	_
32	glucose	_	_	NN	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	reaction	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	more	_	_	RBR	_	_	_	_	_
5	efficient	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	comparison	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	transesterification	_	_	NN	_	_	_	_	_
10	reaction	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	2-methoxy-1,4-naphthoquinones	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	recently	_	_	RB	_	_	_	_	_
17	discovered	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	us	_	_	PRP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	synthesized	_	_	VBD	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	series	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	6-(1,4-naphtoquinonyl)-D-glucose	_	_	NN	_	_	_	_	_
9	conjugates	_	_	NNS	_	_	_	_	_
10	containing	_	_	VBG	_	_	_	_	_
11	diprotected	_	_	VBN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	monoprotected	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	unprotected	_	_	JJ	_	_	_	_	_
17	glucose	_	_	NN	_	_	_	_	_
18	residues	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	line	_	_	NN	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	our	_	_	PRP$	_	_	_	_	_
5	hypotheses	_	_	NNS	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	glucose-conjugated	_	_	JJ	_	_	_	_	_
8	compounds	_	_	NNS	_	_	_	_	_
9	revealed	_	_	VBD	_	_	_	_	_
10	higher	_	_	JJR	_	_	_	_	_
11	selectivity	_	_	NN	_	_	_	_	_
12	towards	_	_	IN	_	_	_	_	_
13	five	_	_	CD	_	_	_	_	_
14	human	_	_	JJ	_	_	_	_	_
15	prostate	_	_	NN	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	lines	_	_	NNS	_	_	_	_	_
19	compared	_	_	VBN	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	five	_	_	CD	_	_	_	_	_
22	non-cancerous	_	_	JJ	_	_	_	_	_
23	lines	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	successful	_	_	JJ	_	_	_	_	_
3	targeting	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	Warburg	_	_	NNP	_	_	_	_	_
7	effect	_	_	NN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	newly	_	_	RB	_	_	_	_	_
11	synthesized	_	_	VBN	_	_	_	_	_
12	glucose	_	_	NN	_	_	_	_	_
13	derivatives	_	_	NNS	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	strongly	_	_	RB	_	_	_	_	_
16	suggested	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	following	_	_	VBG	_	_	_	_	_
20	findings	_	_	NNS	_	_	_	_	_
21	:	_	_	:	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	a	_	_	CD	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	correlation	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	cytotoxicity	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	selectivity	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	synthesized	_	_	VBN	_	_	_	_	_
33	conjugates	_	_	NNS	_	_	_	_	_
34	with	_	_	IN	_	_	_	_	_
35	higher	_	_	JJR	_	_	_	_	_
36	expression	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	GLUT-1	_	_	NN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	human	_	_	JJ	_	_	_	_	_
41	prostate	_	_	NN	_	_	_	_	_
42	cancer	_	_	NN	_	_	_	_	_
43	cells	_	_	NNS	_	_	_	_	_
44	;	_	_	:	_	_	_	_	_
45	(	_	_	-LRB-	_	_	_	_	_
46	b	_	_	NN	_	_	_	_	_
47	)	_	_	-RRB-	_	_	_	_	_
48	inhibition	_	_	NN	_	_	_	_	_
49	of	_	_	IN	_	_	_	_	_
50	cytotoxicity	_	_	NN	_	_	_	_	_
51	of	_	_	IN	_	_	_	_	_
52	the	_	_	DT	_	_	_	_	_
53	conjugates	_	_	NNS	_	_	_	_	_
54	by	_	_	IN	_	_	_	_	_
55	addition	_	_	NN	_	_	_	_	_
56	of	_	_	IN	_	_	_	_	_
57	glucose	_	_	NN	_	_	_	_	_
58	to	_	_	TO	_	_	_	_	_
59	the	_	_	DT	_	_	_	_	_
60	media	_	_	NN	_	_	_	_	_
61	;	_	_	:	_	_	_	_	_
62	c	_	_	NN	_	_	_	_	_
63	)	_	_	-RRB-	_	_	_	_	_
64	ability	_	_	NN	_	_	_	_	_
65	of	_	_	IN	_	_	_	_	_
66	the	_	_	DT	_	_	_	_	_
67	compounds	_	_	NNS	_	_	_	_	_
68	to	_	_	TO	_	_	_	_	_
69	inhibit	_	_	VB	_	_	_	_	_
70	a	_	_	DT	_	_	_	_	_
71	glucose	_	_	NN	_	_	_	_	_
72	uptake	_	_	NN	_	_	_	_	_
73	by	_	_	IN	_	_	_	_	_
74	cancer	_	_	NN	_	_	_	_	_
75	cells	_	_	NNS	_	_	_	_	_
76	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	general	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	binding	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	quinone	_	_	NN	_	_	_	_	_
9	core	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	glucose	_	_	NN	_	_	_	_	_
13	moiety	_	_	NN	_	_	_	_	_
14	lead	_	_	VBP	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	an	_	_	DT	_	_	_	_	_
17	increased	_	_	VBN	_	_	_	_	_
18	water	_	_	NN	_	_	_	_	_
19	solubility	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	selectivity	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	at	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	same	_	_	JJ	_	_	_	_	_
6	time	_	_	NN	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	resulted	_	_	VBD	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	absolute	_	_	JJ	_	_	_	_	_
12	cytotoxicity	_	_	NN	_	_	_	_	_
13	decrease	_	_	NN	_	_	_	_	_
14	when	_	_	WRB	_	_	_	_	_
15	compared	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	methoxy	_	_	NN	_	_	_	_	_
18	derivatives	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	most	_	_	RBS	_	_	_	_	_
21	probably	_	_	RB	_	_	_	_	_
22	due	_	_	JJ	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	increased	_	_	VBN	_	_	_	_	_
26	polarity	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	molecule	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	should	_	_	MD	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	noted	_	_	VBN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	normal	_	_	JJ	_	_	_	_	_
8	prostate	_	_	NN	_	_	_	_	_
9	cells	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	known	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	have	_	_	VB	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	active	_	_	JJ	_	_	_	_	_
16	glycolysis	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	also	_	_	RB	_	_	_	_	_
19	consume	_	_	VB	_	_	_	_	_
20	significant	_	_	JJ	_	_	_	_	_
21	amount	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	glucose	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	reviewed	_	_	VBN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	cells	_	_	NNS	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	affected	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	Warburg	_	_	NNP	_	_	_	_	_
12	effect	_	_	NN	_	_	_	_	_
13	targeting	_	_	VBG	_	_	_	_	_
14	therapeutics	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	vivo	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	frequently	_	_	RB	_	_	_	_	_
4	patients	_	_	NNS	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	advanced	_	_	JJ	_	_	_	_	_
7	prostate	_	_	NN	_	_	_	_	_
8	cancer	_	_	NN	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	had	_	_	VBN	_	_	_	_	_
11	local	_	_	JJ	_	_	_	_	_
12	treatment	_	_	NN	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	their	_	_	PRP$	_	_	_	_	_
15	primary	_	_	JJ	_	_	_	_	_
16	tumors	_	_	NNS	_	_	_	_	_
17	leaving	_	_	VBG	_	_	_	_	_
18	no	_	_	DT	_	_	_	_	_
19	vital	_	_	JJ	_	_	_	_	_
20	tissue	_	_	NN	_	_	_	_	_
21	behind	_	_	IN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	cytoreduction	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	remaining	_	_	VBG	_	_	_	_	_
8	prostate	_	_	NN	_	_	_	_	_
9	tissue	_	_	NN	_	_	_	_	_
10	maybe	_	_	RB	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	pleasant	_	_	JJ	_	_	_	_	_
13	side	_	_	NN	_	_	_	_	_
14	effect	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	order	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	avoid	_	_	VB	_	_	_	_	_
19	local	_	_	JJ	_	_	_	_	_
20	complications	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_

